Shares of AIM ImmunoTech Inc. (AIM) are rising above 13% in pre-market today, extending the 190.48% rally in the previous session. We alerted readers to this stock yesterday at $3.34. The stock ran up to $7.11 yesterday and closed Monday's trade at $6.10, up $4.00 or 190.48%.
On March 9, the immuno-pharma company announced that the National Institute of Infectious Diseases or NIID in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com